Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M. Sholl, Laura E. MacConaill, Adrian M. Dubuc et al.|JCI Insight|2016Cited by 447
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D. Engstrom, James G. Christensen, Ruth Aranda et al.|Clinical Cancer Research|2017Cited by 147